CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 06 novembre 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un portefeuille de médicaments dédiés aux situations d’urgence, publie conformément aux articles 223-16 du Règlement général de l’AMF et L.233-8 II du Code de commerce, le nombre total de droits de vote et d’actions composan...
The tariff war has eased, but with Trump, uncertainty has become a guarantee. While the macro-economic impact has been limited so far, the prolonged situation could still result in significant and long-lasting economic damage. We are maintaining a defensive stance in our Benelux Dynamic Top Pick List. The Federal Reserve (FED) has started its easing cycle, but the final amount of interest rate cuts is uncertain. The European Central Bank (ECB) has now largely completed its interest rate cutting ...
This morning Vopak released its 3Q25 earnings. These confirmed with an in line operating performance (see earlier FRN this morning). Amidst all tariff related uncertainty and unfavourable FX dynamics, the report and maintained FY guidance underlines the defensiveness of the business model. Occupancy is holding up well and in the mean time large investments in Gas/Industrial terminals are being taken and properly executed. This bodes well for 2027 EBITDA growth. The analyst call had limited news ...
Ahold Delhaize: Strong beat driven by one-offs Alfen: Bull bear fight continues bpost: 3Q25 results in line with INGF but miss vs consensus, FY25 outlook fine-tuned to top-end CM.com: Takeover offer from Bird Coca-Cola Europacific Partners: Refreshing D'Ieteren: Belron peer Driven Brands 3Q25 talks of lower Q4, choppiness in Collision and Direct Repair Exor: Ferrari reassures with strong 3Q25, improved guidance KPN: Strategy update reassures, largely in line, with solid cash returns expec...
Vopak once more confirmed with an in line operating performance. Proportional EBITDA (excl. exceptionals) of €287m in line with €291m company compiled CSS and a tad below €294m KBC est. The full year EBITDA outlook bandwidth was maintained. Occupancy rates are holding up well at 90%. This is a slight drop vs. last quarter but reflects timing of contract renewals. 3Q25 OCR of 14.7% is flattish vs. 2Q25 reflecting seasonal timing of capex phasing. Amidst all tariff related uncertainty and unfavour...
Vopak reports strong performance, driven by a resilient portfolio The Netherlands, 5 November 2025 Vopak reports strong performance, driven by a resilient portfolioKey highlights Improve Net profit -including exceptional items- increased YTD Q3 2025 by 30% to EUR 407 million and EPS of EUR 3.51 increased by 37% year-on-yearProportional EBITDA -excluding exceptional items1- YTD Q3 2025 of EUR 902 million an increase of 1% year-on-year, absorbing negative currency impact of EUR 18 million year-to-date Proportional operating free cash flow per share YTD Q3 2025 increased by 4% year-on-ye...
The strengthening of the protectionist setup in Europe, while very significant, does not alter our sector hierarchy. We expect Europe to suffer from still soft demand in 2026 and high inventories fuelled by imports set to remain elevated out to H1. We are lowering our estimates for 2026 and 2027 but raising them further out, with our target prices increased by 20% on average as a result. With its focus on the US and a possible speculative dimension, Acerinox's positioning remains attractive. We ...
Le renforcement du cadre protectionniste en Europe, bien que très significatif, ne modifie pas notre hiérarchie sectorielle. Nous pensons que l’Europe devrait pâtir d’une demande encore faible en 2026 et de stocks importants nourris par des importations probablement encore élevées jusqu’au S1. Nous abaissons nos estimations 2026 et 2027 mais les relevons au-delà et nos OC sont donc augmentés de 20% en moyenne. Avec son focus sur les USA et une possible dimension spéculative, nous jugeons le posi...
CROSSJECT annonce la mise à disposition du rapport financier semestriel au 30 juin 2025 Communiqué de presse CROSSJECT annonce la mise à disposition du rapport financier semestriel au 30 juin 2025 DIJON, France – 30 octobre 2025 (20H00 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique internationale spécialisée dans le développement d'auto-injecteurs sans aiguille pour les situations d'urgence, annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des Marchés Financiers son rapport financier semestriel au 30 juin 2025. Le rapp...
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 29 octobre 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un portefeuille de médicaments dédiés aux situations d’urgence, publie conformément aux articles 223-16 du Règlement général de l’AMF et L.233-8 II du Code de commerce, le nombre total de droits de vote et d’actions composant...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.